New drug combo aims to shrink tough prostate cancers before surgery
NCT ID NCT07163910
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This study tests whether adding the drug homoharringtonine to standard hormone therapy before prostate removal can improve outcomes for men with high-risk or advanced prostate cancer. About 93 participants will receive the combination before surgery. The goal is to see if this approach reduces cancer more effectively than hormone therapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongda Hospital
RECRUITINGNanjing, Jiangsu, 210009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.